Poseida Therapeutics Inc Stock News

Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncology Advancing innovative strategies to overcome the uni...

SAN DIEGO , Nov. 11, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that the Company will participate in the following upcoming investor conferences: Stifel 2024 Healthcare Conference Date: M...

Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target  Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date  Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with 91% overall response rate and differentiated safety p...

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH SAN DIEGO , Nov. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage ...

Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Scientific Meeting SAN DIEGO , Oct. 24, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, aut...

Allogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma Nomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026 Poseida Cell Therapy R&D Day to take place on Thursday, November 14 at 7 am PT / 10 am ET SAN DIEGO , Oct. 17, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stag...

Inclusion on list recognizes Poseida for employee sentiment and satisfaction SAN DIEGO , Oct. 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced its inclusion in Newsweek Magazine's annual America's Top M...

Positive interim results released from phase 1/1b study using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory Multiple Myeloma. The global multiple myeloma market is projected to reach $44.22 billion by 2032. Interim data update for use of P-CD19CD20-ALLO1 in ongoing phase 1 study targeting patients with B-cell malignancies expected in the 2nd half of 2024 pending coordinati...